all the information, none of the junk | biotech • healthcare • life sciences

The “Augmenix” Question: Can Amar Sawhney Do It Again with Latest Hydrogel Startup?

Xconomy Boston — 

Amar Sawhney has turned a number of products based on his hydrogel inventions into FDA-approved products and rich paydays for his investors. With several successful hydrogel ventures already under his belt, Sawhney is at it again with Augmenix, a Waltham, MA, medical-devices startup developing the versatile materials for an unproven use: To prevent radiation damage to healthy tissue during cancer therapy.

One of Sawhney’s hydrogels—water-based, biodegradable polymers that turn from liquid to solid in the body—has been approved by the FDA as a temporary surgical sealant for cranial and spinal cord procedures. Confluent Surgical, the Waltham medical devices startup launched to develop those uses of hydrogels, was scooped up by then-Tyco Healthcare/now-Covidien (NYSE:COV) in summer 2006 for $245 million. Within a few months of the buyout, Sawhney and his partners formed I-Therapeutix, also of Waltham, to commercialize a hydrogel product, dubbed I-Zip, to seal wounds on the eye after cataract surgeries. The I-Zip sealant is expected to be eligible for market clearance sometime next year.

“The FDA is very familiar with the technology now,” Sawhney says, “so that is very helpful.”

When I spoke to Sawhney last week to get an update on I-Therapeutix, he let me in on his latest startup, Augmenix, which he quietly launched early this year and which operates in the same office as I-Therapeutix. Call it Sawhney’s hydrogel headquarters; he serves as CEO of both firms.

Augmenix aims to extend the utility of hydrogels beyond surgical sealants, initially by developing the materials to form spacers between healthy tissues and cancer-riddled prostates undergoing external-beam or seed-based (brachytherapy) radiation, Sawhney says. The hydrogel spacers are intended to move healthy tissues adjacent to the prostate—primarily rectal tissue—away from the radiation beams or seeds. The materials are currently being tested in animals and cadavers to provide data needed for human studies. Augmenix may also develop a hydrogel product to treat adult incontinence (a nice word for lack of bladder and bowel control) but he wasn’t ready to specify how that would work.

William Noyes, an oncologist who operates a radiation clinic in Grand Forks, ND, came up with and patented the idea for Augmenix’s spacer. Sawhney says that he and his longtime business partner, Fred Khosravi, have licensed Noyes’ patent and combined it with their own patents for hydrogels. (In fact, Sawhney and Khosravi control the hydrogel patents licensed to Confluent, I-Therapeutix and several other startups through a holding company called Incept.)

Augmenix has raised a seed round of $1 million from Incept, angel investors, and Pinnacle Ventures and Versant Ventures—both California VC firms that invested in the $6 million Series B round of financing for I-Therapeutix earlier this year. Sawhney says he expects Augmenix to raise a $6 million round of VC in early 2009 to fund clinical trials.

Of course, further studies will be needed to show whether Sawhney’s hydrogels ultimately make effective spacers for men undergoing radiation therapy for prostate cancer. But he said he performed successful tests with hydrogels and radiation at one of the early biomaterials companies he formed, Focal, formerly of Lexington, MA. By the way, Genzyme (NASDAQ:GENZ) acquired Focal in 2001 to become part of its biosurgery unit.

By posting a comment, you agree to our terms and conditions.

2 responses to “The “Augmenix” Question: Can Amar Sawhney Do It Again with Latest Hydrogel Startup?”

  1. Jim says:

    Just remember, Focal investors like myself lost almost everything when Genzyme cut off further funding so they could by Focal for next to nothing in Genzyme Biosurgery stock and then took Genzyme Biosurgery shareholders through their forced sale of the company at a price less than the actual market value on the day of the sale. All this done after secret meetings where Genzyme’s own people estimated the value at approximately 8 to 45 times the purchase price. All very legal and nice and tidy.

  2. Alex says:

    I was employed by Focal from 93-96 and would like to mention a few things regarding Amar Sahwney.First in no way should one confuse Amar with having anything to do with the mis-managed deal between Genzyme or the evntual “fall of Focal”. Amar was an employee of Focal, young post doc graduate and the lead scientist for the company’s technolgy. Thereby, he had nothing to do with or had an inputy in the business affairs or overall direction of the company obviously handled by an inept management team. We all lost something from Focal and its’ demise but hopefully like Amar, you learn something from your experience,in this case what not to do, apply it and move on. It sounds like he is being blamed for the failure of a company he had no control of nor even a say in direction. Given his succesful track record since Focal, I would’ve preferred that he did.